Comparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract
Polyendocrine metabolic ovarian syndrome (PMOS), previously known by the name 'polycystic ovary syndrome (PCOS),' is a common and complex endocrine-metabolic disorder affecting approximately one in eight women. PMOS is increasingly regarded as a multisystem disorder rather than only a gynaecological condition. Exclusive of weight loss, metformin has been the mainstay pharmacological therapy in the treatment of PMOS; a new contender for the management of this condition is liraglutide. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RAs) and has gained increasing interest because it targets appetite regulation, body weight, and glycemic control as well as insulin sensitivity. There remains no comprehensive and up-to-date synthesis specifically comparing liraglutide versus metformin across clinically important outcomes in women with PMOS. This systematic review and meta-analysis aims to comprehensively evaluate these outcomes and provide evidence to guide individualized therapeutic decision-making. This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines (PRISMA). The research protocol was registered under the International Prospective Register of Systematic Reviews (PROSPERO), and the proposal is available under registration number CRD420261435182. No statistically significant difference in BMI between liraglutide and metformin (mean difference (MD)=0.25, 95% confidence interval (CI):…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.